CVE-2024-9030

Public Exploit
CodeCanyon CRMGo SaaS note cross site scripting

Description

A vulnerability classified as problematic was found in CodeCanyon CRMGo SaaS 7.2. This vulnerability affects unknown code of the file /deal/{note_id}/note. The manipulation of the argument notes leads to cross site scripting. The attack can be initiated remotely. The exploit has been disclosed to the public and may be used.

Category

5.3
CVSS
Severity: Medium
CVSS 4.0 •
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.05%
Third-Party Advisory bytium.com Third-Party Advisory vuldb.com
Affected: CodeCanyon CRMGo SaaS
Published at:
Updated at:

References

Link Tags
https://vuldb.com/?id.278200 third party advisory vdb entry technical description
https://vuldb.com/?ctiid.278200 signature permissions required
https://bytium.com/stored-xss-vulnerabilities-in-crmgo-sass-version-7-2/ third party advisory exploit

Frequently Asked Questions

What is the severity of CVE-2024-9030?
CVE-2024-9030 has been scored as a medium severity vulnerability.
How to fix CVE-2024-9030?
To fix CVE-2024-9030, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2024-9030 being actively exploited in the wild?
It is possible that CVE-2024-9030 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-9030?
CVE-2024-9030 affects CodeCanyon CRMGo SaaS.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.